Literature DB >> 25903333

A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Mariana Baz1, Myeisha Paskel1, Yumiko Matsuoka1, James R Zengel2, Xing Cheng2, John J Treanor3, Hong Jin2, Kanta Subbarao4.   

Abstract

UNLABELLED: H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects. IMPORTANCE: Although natural infection of humans with an avian H3N8 influenza virus has not yet been reported, this influenza virus subtype has already crossed the species barrier and productively infected mammals. Pandemic preparedness is an important public health priority. Therefore, we generated a live attenuated avian H3N8 vaccine candidate and demonstrated that a single dose of the vaccine was highly immunogenic and protected mice and ferrets against homologous and heterologous H3N8 avian viruses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903333      PMCID: PMC4468475          DOI: 10.1128/JVI.00280-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.

Authors:  Grace L Chen; Elaine W Lamirande; Chin-Fen Yang; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine.

Authors:  G J Gorse; M J Campbell; E E Otto; D C Powers; G W Chambers; F K Newman
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

3.  Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.

Authors:  Hualan Chen; Kanta Subbarao; David Swayne; Qi Chen; Xiuhua Lu; Jacqueline Katz; Nancy Cox; Yumiko Matsuoka
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

4.  Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

Authors:  J H C M Kreijtz; R Bodewes; G van Amerongen; T Kuiken; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Vaccine       Date:  2006-09-07       Impact factor: 3.641

Review 5.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

6.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

Authors:  Eric Plennevaux; Eric Sheldon; Mark Blatter; Mary-Kate Reeves-Hoché; Martine Denis
Journal:  Lancet       Date:  2009-12-15       Impact factor: 79.321

7.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

8.  Isolation and molecular characterization of equine H3N8 influenza viruses from pigs in China.

Authors:  Jiagang Tu; Hongbo Zhou; Taozhen Jiang; Chun Li; Anding Zhang; Xuebo Guo; Wei Zou; Huanchun Chen; Meilin Jin
Journal:  Arch Virol       Date:  2009-04-26       Impact factor: 2.574

9.  An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.

Authors:  Kawsar R Talaat; Ruth A Karron; Philana H Liang; Bridget A McMahon; Catherine J Luke; Bhagvanji Thumar; Grace L Chen; Ji-Young Min; Elaine W Lamirande; Hong Jin; Kathy L Coelingh; George W Kemble; Kanta Subbarao
Journal:  Influenza Other Respir Viruses       Date:  2012-03-14       Impact factor: 4.380

10.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

View more
  4 in total

1.  Cross-Species Infectivity of H3N8 Influenza Virus in an Experimental Infection in Swine.

Authors:  Alicia Solórzano; Emanuela Foni; Lorena Córdoba; Massimiliano Baratelli; Elisabetta Razzuoli; Dania Bilato; María Ángeles Martín del Burgo; David S Perlin; Jorge Martínez; Pamela Martínez-Orellana; Lorenzo Fraile; Chiara Chiapponi; Massimo Amadori; Gustavo del Real; María Montoya
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Authors:  Rita Czakó; Leatrice Vogel; Troy Sutton; Yumiko Matsuoka; Florian Krammer; Zhongying Chen; Hong Jin; Kanta Subbarao
Journal:  Vaccine       Date:  2018-03-01       Impact factor: 3.641

3.  Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines.

Authors:  Saborni Chakraborty; Vamsee V A Mallajosyula; Troy C Sutton; Elaine W Lamirande; Ketaki Ganti; Kevin W Bock; Ian N Moore; Raghavan Varadarajan; Kanta Subbarao
Journal:  NPJ Vaccines       Date:  2017-12-15       Impact factor: 7.344

4.  Influenza A (H10N7) Virus Causes Respiratory Tract Disease in Harbor Seals and Ferrets.

Authors:  Judith M A van den Brand; Peter Wohlsein; Sander Herfst; Rogier Bodewes; Vanessa M Pfankuche; Marco W G van de Bildt; Frauke Seehusen; Christina Puff; Mathilde Richard; Ursula Siebert; Kristina Lehnert; Theo Bestebroer; Pascal Lexmond; Ron A M Fouchier; Ellen Prenger-Berninghoff; Werner Herbst; Marion Koopmans; Albert D M E Osterhaus; Thijs Kuiken; Wolfgang Baumgärtner
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.